![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CXCL5 |
Gene summary for CXCL5 |
![]() |
Gene information | Species | Human | Gene symbol | CXCL5 | Gene ID | 6374 |
Gene name | C-X-C motif chemokine ligand 5 | |
Gene Alias | ENA-78 | |
Cytomap | 4q13.3 | |
Gene Type | protein-coding | GO ID | GO:0002237 | UniProtAcc | P42830 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6374 | CXCL5 | ATC09 | Human | Thyroid | ATC | 1.01e-35 | 1.71e+00 | 0.2871 |
6374 | CXCL5 | ATC1 | Human | Thyroid | ATC | 2.88e-35 | 1.82e+00 | 0.2878 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
CXCL5 | ACKR1 | CXCL5_ACKR1 | CXCL | Breast | Healthy |
CXCL5 | ACKR1 | CXCL5_ACKR1 | CXCL | Endometrium | EEC |
CXCL5 | CXCR2 | CXCL5_CXCR2 | CXCL | Endometrium | EEC |
CXCL5 | ACKR1 | CXCL5_ACKR1 | CXCL | Esophagus | ESCC |
CXCL5 | ACKR1 | CXCL5_ACKR1 | CXCL | HNSCC | OSCC |
CXCL5 | ACKR1 | CXCL5_ACKR1 | CXCL | HNSCC | Precancer |
CXCL5 | CXCR2 | CXCL5_CXCR2 | CXCL | HNSCC | Precancer |
CXCL5 | ACKR1 | CXCL5_ACKR1 | CXCL | THCA | Cancer |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CXCL5 | SNV | Missense_Mutation | c.251N>C | p.Leu84Pro | p.L84P | P42830 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-BG-A0MQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CXCL5 | SNV | Missense_Mutation | novel | c.100N>G | p.Ile34Val | p.I34V | P42830 | protein_coding | tolerated(0.3) | benign(0) | TCGA-BG-A0VT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
CXCL5 | SNV | Missense_Mutation | c.122N>T | p.Ala41Val | p.A41V | P42830 | protein_coding | deleterious(0.02) | possibly_damaging(0.565) | TCGA-BG-A0YV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
CXCL5 | SNV | Missense_Mutation | c.188T>G | p.Ile63Ser | p.I63S | P42830 | protein_coding | deleterious(0) | probably_damaging(0.939) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CXCL5 | SNV | Missense_Mutation | c.136G>A | p.Glu46Lys | p.E46K | P42830 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CXCL5 | SNV | Missense_Mutation | c.17N>C | p.Ser6Thr | p.S6T | P42830 | protein_coding | tolerated(0.14) | probably_damaging(0.971) | TCGA-QS-A5YQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR | |
CXCL5 | SNV | Missense_Mutation | novel | c.77N>C | p.Leu26Pro | p.L26P | P42830 | protein_coding | deleterious(0.03) | probably_damaging(0.997) | TCGA-G3-A3CG-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Targeted Molecular therapy | sorafenib | SD |
CXCL5 | SNV | Missense_Mutation | c.265N>A | p.Glu89Lys | p.E89K | P42830 | protein_coding | tolerated(0.32) | benign(0.122) | TCGA-18-3409-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
CXCL5 | SNV | Missense_Mutation | c.215N>T | p.Gly72Val | p.G72V | P42830 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-39-5016-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6374 | CXCL5 | DRUGGABLE GENOME | hmg coa reductase inhibitors | 18769620 |
Page: 1 |